title: Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer.
abstract: OBJECTIVE
  The purpose of this article is to study relationships between MRI-based prostate volume and volume-adjusted serum prostate-specific antigen (PSA) concentration estimates and prostate cancer Gleason score.
  
  
  METHODS
  The study included 61 patients with prostate cancer (average age, 63.3 years; range 52-75 years) who underwent MRI before prostatectomy. A semiautomated and MRI-based technique was used to estimate total and central gland prostate volumes, central gland volume fraction (central gland volume divided by total prostate volume), PSA density (PSAD; PSA divided by total prostate volume), and PSAD for the central gland (PSA divided by central gland volume). These MRI-based volume and volume-adjusted PSA estimates were compared with prostatectomy specimen weight and Gleason score by using Pearson (r) or Spearman (ρ) correlation coefficients.
  
  
  RESULTS
  The estimated total prostate volume showed a high correlation with reference standard volume (r = 0.94). Of the 61 patients, eight (13.1%) had a Gleason score of 6, 40 (65.6%) had a Gleason score of 7, seven (11.5%) had a Gleason score of 8, and six (9.8%) had a Gleason score of 9 for prostate cancer. The Gleason score was significantly correlated with central gland volume fraction (ρ = -0.42; p = 0.0007), PSAD (ρ = 0.46; p = 0.0002), and PSAD for the central gland (ρ = 0.55; p = 0.00001).
  
  
  CONCLUSIONS
  Central gland volume fraction, PSAD, and PSAD for the central gland estimated from MRI examinations show a modest but significant correlation with Gleason score and have the potential to contribute to personalized risk assessment for significant prostate cancer.
authors.affiliation: 1 Department of Radiology, University of Chicago, 5841 S Maryland Ave, MC 2026, Chicago, IL 60637.
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Karademir
authors.forename: Dinggang
authors.initials: D
authors.lastname: Shen
authors.forename: Yahui
authors.initials: Y
authors.lastname: Peng
authors.forename: Shu
authors.initials: S
authors.lastname: Liao
authors.forename: Yulei
authors.initials: Y
authors.lastname: Jiang
authors.forename: Ambereen
authors.initials: A
authors.lastname: Yousuf
authors.forename: Gregory
authors.initials: G
authors.lastname: Karczmar
authors.forename: Steffen
authors.initials: S
authors.lastname: Sammet
authors.forename: Shiyang
authors.initials: S
authors.lastname: Wang
authors.forename: Milica
authors.initials: M
authors.lastname: Medved
authors.forename: Tatjana
authors.initials: T
authors.lastname: Antic
authors.forename: Scott
authors.initials: S
authors.lastname: Eggener
authors.forename: Aytekin
authors.initials: A
authors.lastname: Oto
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D003287:Contrast Media; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; D003287:Contrast Media; C064925:gadodiamide; D017430:Prostate-Specific Antigen; D019786:Gadolinium DTPA